Mandate

Vinge advises Klövern on its offer for Agora

Klövern AB (publ) has, through its indirectly wholly-owned subsidiary Dagon Sverige AB, made a public cash offer to the shareholders of A Group Of Retail Assets Sweden AB (publ) (Nasdaq First North).

Klövern is a listed real estate company committed with closeness and commitment to offering attractive commercial premises, and developing housing, in growth regions. The public offer entails that the shareholders in Agora are offered a cash consideration of SEK 30.00 for each class A and class B share and SEK 275.00 for each preference share in Agora. The offer implies a value of MSEK 1,023 for all shares in Agora.

Vinge advises Klövern.  The Vinge team is headed by Dain Hård Nevonen and also includes Rikard Lindahl, Malte Hedlund and Anna-Karin Alin, as well as Grant McKelvey and Alva Hägglund (on competition matters).

Related

Vinge has advised Oncopeptides in connection with its rights issue

Vinge has advised Oncopeptides AB (publ) in connection with a fully guaranteed rights issue which will provide Oncopeptides with proceeds of approximately SEK 150 million before deduction of transaction costs.
August 28, 2025

Vinge advises Main Capital and Unik in connection with the acquisition of LEB System Aktiebolag

Vinge has advised Unik International ApS (“Unik”), a Danish Housing and Property Management software provider, in connection with the acquisition of LEB System Aktiebolag. The synergistic acquisition is expected to complement and expand Unik’s offering and has a strong strategic fit with Unik and is in line with the company’s internationalization strategy in the Nordic Property Management software market.
August 28, 2025

Vinge has advised Xspray Pharma in connection with its rights issue and debt refinancing

Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 130 million before transaction costs, with an over-allotment issue of approximately SEK 20 million, and refinancing of an existing loan.
August 28, 2025